Log in to search using one of your social media accounts:

 

Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population ‐based study among older breast cancer patients

CONCLUSIONSAdjuvant chemotherapy is associated with a small but significant increase in the risk of AML and MDS, especially with regimens that include A. Longer follow‐up is needed to confirm that risk is not increased with the recently adopted TC regimen. Cancer 2017. © 2017 American Cancer Society.
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research

Related Links:

This year Forbes' 30 Under 30 health care honorees are recognized for fighting cancer, designing prosthetic legs and gene editing applications, among other advances. The annual roundup features 600 individuals from 20 different industries, and 10 Bay Area individuals in health care made the list. Genome editing technology CRISPR continues to fuel scientists in the health field. Kunwoo Lee, a scientist at University of California, Berkeley, co-founded GenEdit to use CRISPR components to develop…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
Scientists are reporting progress on a blood test to detect many types of cancer at an early stage
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
CONCLUSION: Although all of the appendectomy samples were normal macroscopically, data from this study suggest that all specimens should be sent for routine investigation. KEY WORDS: Appendicitis, Appendectomy, Carcinoid, Mucocele, Endometriosis. PMID: 29339597 [PubMed - in process]
Source: Annali Italiani di Chirurgia - Category: Surgery Tags: Ann Ital Chir Source Type: research
CONCLUSIONS: The most relevant prognostic factor in patients with hepatic colorectal cancer dissemination is the timing of metastasis; the metachronous lesions present better survival when surgically treated. KEY WORDS: Colorectal cancer, Liver, Metastasis, Surgery. PMID: 29339595 [PubMed - in process]
Source: Annali Italiani di Chirurgia - Category: Surgery Tags: Ann Ital Chir Source Type: research
ConclusionsThe burden of tAML/tMDS in Victoria is likely to be underestimated. Linkage between VCR and clinical registries is needed to provide more accurate insights.
Source: Internal Medicine Journal - Category: Internal Medicine Authors: Tags: Original Article Source Type: research
We examined acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) events among 9679 women treated for breast cancer on four adjuvant Alliance for Clinical Trials in Oncology trials with>90  months of follow-up in order to better characterize the risk for AML/MDS in older patients receiving anthracyclines.MethodsWe used multivariable Cox regression to examine factors associated with AML/MDS, adjusting for age ( ≥65 vs.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Authors: Bertoli S, Sterin A, Tavitian S, Oberic L, Ysebaert L, Bouabdallah R, Vergez F, Sarry A, Bérard E, Huguet F, Laurent G, Prébet T, Vey N, Récher C Abstract Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous entity most frequently related to breast cancer or lymphoproliferative diseases (LD). Population-based studies have reported an increased risk of t-AML after treatment of lymphomas. The aim of this study was to describe the characteristics and outcome of 80 consecutive cases of t-AML following treatment of LD. t-AML accounted for 2.3% of all AML cases, occurred 60 mont...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
The therapy related myeloid neoplasms (t-MN) include the cases of therapy related myelodysplastic syndrome (t-MDS) and therapy related acute myeloid leukemia (t-AML) that occurs as a late complication of chemotherapy and/or radiotherapy administered to treat a previous neoplastic disease [1]. The alkylating agents and the topoisomerase II inhibitors are commonly implicated in the etiology of the disease, with a shorter latency period, 1 –5 years, for the topoisomerase II inhibitors. Most of patients with t-AML/t-MDS show an abnormal karyotype.
Source: Leukemia Research - Category: Hematology Authors: Tags: Editorial Source Type: research
Abstract Risk of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) post-breast cancer treatment with adjuvant chemotherapy and granulocyte colony-stimulating factors (G-CSF) is not fully characterized. Our objective was to estimate MDS/AML risk associated with specific breast cancer treatments. We conducted a retrospective cohort study of women aged ≥66 years with stage I–III breast cancer between 2001 and 2009 using the Surveillance, Epidemiology, and End Results-Medicare database. Women were classified as receiving treatment with radiation, chemotherapy, and/or G-CSF. We used multivar...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Abstract Bone marrow cells and peripheral blood mononuclear cells obtained from both acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients contain upregulated levels of cell surface antigen CD33 compared with healthy controls. This difference enables the use of humanized anti-CD33 antibody conjugated to cytotoxic agents for CD33 targeted immunotherapy. However, the expression of the membrane-bound drug transporter P-glycoprotein (P-gp) has been shown to be critical for resistance against the cytotoxicity of a humanized anti-CD33 antibody conjugated to maytansine-derivative DM4. The aim of the pr...
Source: European Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharm Sci Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Docetaxel | Epidemiology | Leukemia | Medicare | Myelodysplastic Syndrome | Statistics | Study | Taxotere